REVerse Intestinal Metaplasia in the Stomach (REVISE)

Summary

This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment. A secondary aim will be to generate gastric organoids from patient-derived samples to test the effects of pyrvinium in vitro in patient-derived samples, and also to identify new drugs that may help reverse gastric intestinal metaplasia.

Timeline

Start

2025-12-15

Primary completion

2026-10-01

Completion

2026-10-01

Drugs

Indications